{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:51:56Z","timestamp":1772121116741,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.jhep.2014.02.021","type":"journal-article","created":{"date-parts":[[2014,3,6]],"date-time":"2014-03-06T04:02:46Z","timestamp":1394078566000},"page":"139-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Synergistic interaction between genetics and disease on pravastatin disposition"],"prefix":"10.1016","volume":"61","author":[{"given":"John D.","family":"Clarke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhiannon N.","family":"Hardwick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"April D.","family":"Lake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Lickteig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Goedken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curtis D.","family":"Klaassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan J.","family":"Cherrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2014.02.021_b0005","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2174\/138920012803341302","article-title":"Drug disposition in pathophysiological conditions","volume":"13","author":"Gandhi","year":"2012","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.jhep.2014.02.021_b0010","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/pr.110.002857","article-title":"Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake","volume":"63","author":"Niemi","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jhep.2014.02.021_b0015","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1517\/17425255.2012.656087","article-title":"Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions","volume":"8","author":"Clarke","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.jhep.2014.02.021_b0020","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.clpt.2006.01.010","article-title":"Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin","volume":"79","author":"Igel","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jhep.2014.02.021_b0025","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/01.fpc.0000170913.73780.5f","article-title":"Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1\u22175, SLCO1B1\u221715, and SLCO1B1\u221715+C1007G, by using transient expression systems of HeLa and HEK293 cells","volume":"15","author":"Kameyama","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jhep.2014.02.021_b0030","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients \u2013 the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jhep.2014.02.021_b0035","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3949\/ccjm.78a.10073","article-title":"Statin myopathy: a common dilemma not reflected in clinical trials","volume":"78","author":"Fernandez","year":"2011","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.jhep.2014.02.021_b0040","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2125.2007.02892.x","article-title":"SLCO1B1 521TC functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients","volume":"64","author":"Zhang","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jhep.2014.02.021_b0045","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/clpt.2012.57","article-title":"The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy","volume":"92","author":"Wilke","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jhep.2014.02.021_b0050","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.jacc.2009.04.053","article-title":"The SLCO1B1\u22175 genetic variant is associated with statin-induced side effects","volume":"54","author":"Voora","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jhep.2014.02.021_b0055","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/clpt.2009.197","article-title":"Transporter pharmacogenetics and statin toxicity","volume":"87","author":"Niemi","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jhep.2014.02.021_b0060","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","article-title":"Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction","volume":"64","author":"Verbeeck","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jhep.2014.02.021_b0065","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1124\/dmd.111.040592","article-title":"Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human Non-alcoholic fatty liver disease","volume":"39","author":"Lake","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jhep.2014.02.021_b0070","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3109\/03602532.2011.577781","article-title":"Drug metabolism alterations in Non-alcoholic fatty liver disease","volume":"43","author":"Merrell","year":"2011","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.jhep.2014.02.021_b0075","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejphar.2009.04.002","article-title":"Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats","volume":"613","author":"Fisher","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jhep.2014.02.021_b0080","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1124\/dmd.111.041095","article-title":"Molecular mechanism of altered ezetimibe disposition in Non-alcoholic steatohepatitis","volume":"40","author":"Hardwick","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jhep.2014.02.021_b0085","first-page":"Unit 23.1","article-title":"Measuring altered disposition of xenobiotics in experimental models of liver disease","volume":"Chapter 23","author":"Hardwick","year":"2012","journal-title":"Curr Protoc Toxicol"},{"key":"10.1016\/j.jhep.2014.02.021_b0090","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1124\/dmd.109.027466","article-title":"Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of Non-alcoholic fatty liver disease","volume":"37","author":"Fisher","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jhep.2014.02.021_b0095","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for Non-alcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.02.021_b0100","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1124\/dmd.110.035006","article-title":"Diversity in antioxidant response enzymes in progressive stages of human Non-alcoholic fatty liver disease","volume":"38","author":"Hardwick","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jhep.2014.02.021_b0105","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1016\/j.jchromb.2010.08.015","article-title":"Liquid chromatography-tandem mass spectrometric assay for pravastatin and two isomeric metabolites in mouse plasma and tissue homogenates","volume":"878","author":"Sparidans","year":"2010","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.jhep.2014.02.021_b0110","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/j.1440-1746.2008.05543.x","article-title":"Animal models of NASH: getting both pathology and metabolic context right","volume":"23","author":"Larter","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2014.02.021_b0115","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1124\/dmd.113.055996","article-title":"Modeling human non-alcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models","volume":"42","author":"Canet","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jhep.2014.02.021_b0120","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s11883-010-0120-9","article-title":"Evidence-based management of statin myopathy","volume":"12","author":"Harper","year":"2010","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jhep.2014.02.021_b0125","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1124\/mol.108.046458","article-title":"Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2\/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin","volume":"74","author":"Zaher","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jhep.2014.02.021_b0130","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1021\/mp300108c","article-title":"Organic anion-transporting polypeptides 1a\/1b control the hepatic uptake of pravastatin in mice","volume":"9","author":"Iusuf","year":"2012","journal-title":"Mol Pharm"},{"key":"10.1016\/j.jhep.2014.02.021_b0135","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1007\/s11095-012-0792-7","article-title":"Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions","volume":"29","author":"Varma","year":"2012","journal-title":"Pharm Res"},{"key":"10.1016\/j.jhep.2014.02.021_b0140","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.2522\/ptj.20090251","article-title":"Effects of statins on skeletal muscle: a perspective for physical therapists","volume":"90","author":"Di Stasi","year":"2010","journal-title":"Phys Ther"},{"key":"10.1016\/j.jhep.2014.02.021_b0145","doi-asserted-by":"crossref","first-page":"89C","DOI":"10.1016\/j.amjcard.2006.02.030","article-title":"Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force","volume":"97","author":"McKenney","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jhep.2014.02.021_b0150","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/FPC.0b013e3280ef698f","article-title":"Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants","volume":"17","author":"Ho","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jhep.2014.02.021_b0155","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.clpt.2003.12.016","article-title":"Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics","volume":"75","author":"Mwinyi","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jhep.2014.02.021_b0160","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0009-9236(03)00060-2","article-title":"Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics","volume":"73","author":"Nishizato","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jhep.2014.02.021_b0165","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/01.fpc.0000114750.08559.32","article-title":"High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)","volume":"14","author":"Niemi","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.jhep.2014.02.021_b0170","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2133\/dmpk.19.375","article-title":"Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors","volume":"19","author":"Tachibana-Iimori","year":"2004","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.jhep.2014.02.021_b0175","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1007\/s10038-006-0025-1","article-title":"Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy","volume":"51","author":"Takane","year":"2006","journal-title":"J Hum Genet"},{"key":"10.1016\/j.jhep.2014.02.021_b0180","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1124\/dmd.106.014407","article-title":"The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3","volume":"35","author":"Seithel","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jhep.2014.02.021_b0185","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1124\/jpet.103.060194","article-title":"Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human","volume":"308","author":"Nozawa","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jhep.2014.02.021_b0190","doi-asserted-by":"crossref","first-page":"37161","DOI":"10.1074\/jbc.274.52.37161","article-title":"A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters","volume":"274","author":"Hsiang","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2014.02.021_b0195","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1023\/A:1018838405987","article-title":"Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2","volume":"16","author":"Tokui","year":"1999","journal-title":"Pharm Res"},{"key":"10.1016\/j.jhep.2014.02.021_b0200","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/07853890802552437","article-title":"New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)","volume":"41","author":"Ali","year":"2009","journal-title":"Ann Med"},{"key":"10.1016\/j.jhep.2014.02.021_b0205","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s10620-012-2118-3","article-title":"Lipid-lowering agents in Non-alcoholic fatty liver disease and steatohepatitis: human studies","volume":"57","author":"Nseir","year":"2012","journal-title":"Dig Dis Sci"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827814001299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827814001299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:32:38Z","timestamp":1759174358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827814001299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0168827814001299"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2014.02.021","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718305671.793498865","asserted-by":"object"}]},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic interaction between genetics and disease on pravastatin disposition","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2014.02.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2014.03.032","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}